Panacea Index Logo

Command Palette

Search for a command to run...

Psychedelic Medicines in Major Depression: Progress and Future Challenges.

Advances in experimental medicine and biology
January 1, 2021
Jose Carlos Bouso et al. (4 authors)
Journal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to review the safety, efficacy, and neurobiological mechanisms of psychedelic drugs, including ayahuasca, for treating mental disorders such as major depression.

Results Summary

The abstract indicates that clinical trials have assessed ayahuasca's therapeutic potential, suggesting it may be effective as an adjuvant in psychotherapeutic processes, though specific results are not detailed.

Population

Patients with mental disorders, including major depression (specific demographics not provided).

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (2)
InterventionDirectionEndpointPopulationDosageImpactClaim #
psilocybin
neutral
major depression
patients
-
assessed the safety and efficacy
#1
ayahuasca
neutral
major depression
patients
-
assessed the safety and efficacy
#2
Abstract

The volume of research on the therapeutic use of psychedelic drugs has been increasing during the last decades. Partly because of the need of innovative treatments in psychiatry, several studies have assessed the safety and efficacy of drugs like psilocybin or ayahuasca for a wide range of mental disorders, including major depression. The first section of this chapter will offer an introduction to psychedelic research, including a brief historical overview and discussions about appropriate terminology. In the second section, the recently published clinical trials in which psychedelic drugs were administered to patients will be analysed in detail. Then, in the third section, the main neurobiological mechanisms of these drugs will be described, noting that while some of these mechanisms could be potentially associated with their therapeutic properties, they are commonly used as adjuvants in psychotherapeutic processes. The last section suggests future challenges for this groundbreaking field of research and therapy.

Medical Subject Headings (MeSH)
DepressionDepressive Disorder, MajorHallucinogensHumansPsilocybinPsychiatry
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality80/10
Citation Metrics
Total Citations5
Citations/Year1.3
Relative Citation Ratio0.59
NIH Percentile32%
Research Impact Scores
APT Score0.50
Weight Score2.35
Normalized Score0.66
Related Supplements